Clinical Trial Update: Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Radiometabolic Therapy with Lutetium-177 PSMA-617 in metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lutetium-177 PSMA-617 (lutetium Lu-177 PSMA-617)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Metastatic Castration Resistant Prostate Cancer, 68Ga-PSMA PET/CT Positive | Phase 2 | Status: COMPLETED